Review
Accepted on 20 Dec 2024
Angiopoietin-like Protein 4 Dysregulation in Kidney Diseases: A Promising Biomarker and Therapeutic Target
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1475198
Type at least 3 characters
586 articles
Articles
Systematic Review
Accepted on 20 Dec 2024
Incidence of Hyperkalemia RAASi and SGLT-2i Treatment in Individuals with Diabetic Kidney Disease: A Systematic Review and Network Meta-Analysis
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1462965
Correction
Accepted on 20 Dec 2024
Corrigendum：Efficacy of Oroxylin A in ameliorating renal fibrosis with emphasis on Sirt1 activation and TGF-βSmad3 pathway modulation
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1548193
- 217 views
Original Research
Accepted on 18 Dec 2024
High Mobility Group Box 1 (HMGB1) Mediates Nicotine-Induced Podocyte Injury
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1540639
Original Research
Published on 18 Dec 2024
An exploratory study evaluated the 30 most commonly reported medications in the United States food and drug administration’s adverse event reporting system that are associated with the occurrence of kidney stones
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1377679
- 141 views
Original Research
Accepted on 06 Dec 2024
Immunosuppressant nonadherence profile in kidney transplant recipients and the impact of medication adherence on transplant outcomes
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1493166
- 162 views
Original Research
Published on 18 Dec 2024
PM2.5-induced oxidative stress upregulates PLA2R expression in the lung and is involved in the pathogenesis of membranous nephropathy through extracellular vesicles
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1516111
- 127 views
Editorial
Accepted on 17 Dec 2024
Women in Renal Pharmacology: from bench to bedside
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1519295
Original Research
Published on 16 Dec 2024
Ondansetron use is associated with increased risk of acute kidney injury in ICU patients following cardiac surgery: a retrospective cohort study
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1511545
- 236 views
Original Research
Published on 12 Dec 2024
JiangyaTongluo decoction ameliorates tubulointerstitial fibrosis via regulating the SIRT1/PGC-1α/mitophagy axis in hypertensive nephropathy
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1491315
- 367 views
Correction
Published on 12 Dec 2024
Corrigendum: Endoglin aggravates peritoneal fibrosis by regulating the activation of TGF-β/ALK/Smads signaling
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1532797
Original Research
Accepted on 11 Dec 2024
Safety Assessment of Tolvaptan: Real-World Adverse Event Analysis Using the FAERS Database
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1509310
Editorial
Published on 11 Dec 2024
Editorial: Novel pathophysiologic mechanisms and reno-protective pharmacotherapies in diabetic kidney disease
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1531748
- 176 views
Original Research
Published on 11 Dec 2024
Hypoalbuminemia and cisplatin-induced acute kidney injury
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1510477
- 147 views
Systematic Review
Published on 11 Dec 2024
Safety of ACEI/ARB use in the early (<3 months) post kidney transplant period: a systematic review and meta-analysis
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1522558
- 114 views
Original Research
Accepted on 10 Dec 2024
The efficacy and safety of half-dose of glucocorticoid combined with Rituximab versus high-dose of glucocorticoid for initial treatment of Minimal change disease: a single-center experience
in Renal Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1403562